All In Biotech

Drug Trial Radar · NCT05384262

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects With or Without Elevated LDL-C Levels

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

183

Actual

Start

May 18, 2022

Primary completion

Jun 14, 2024

Study completion Jun 14, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
May 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of two parts (Parts A and B). 56 subjects have been planned for Part A and 141 subjects for Part B. Additional subjects may be included for the optional cohorts depending upon emerging data.

Conditions

  • Dyslipidemia

Interventions

  • AZD0780Drug

    Subjects will receive AZD0780 orally as a single ascending dose.

  • AZD0780Drug

    Subjects will receive AZD0780 orally as a multiple ascending dose.

  • AZD0780Drug

    Subjects will receive AZD0780 orally as a single and multiple ascending dose.

  • PlaceboDrug

    Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

  • PlaceboDrug

    Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

  • PlaceboDrug

    Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.

  • RosuvastatinDrug

    Subjects will receive rosuvastatin orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with Adverse EventsTime frame: From Screening (≤ 28 days) until Follow-up Visit (5 to 7 days post-dose for all cohorts, and 9 to 11 days post-dose for subjects from Cohort 3 onwards)

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

  • Research Site

    Brooklyn, Maryland

  • Research Site

    Harrow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.